,i #aagth ,,congress #b;d ,session ,h4 ,r4 #gchi ,,in ,,the ,,house ,,of ,,representatives ,april #d1 #bjbb,mr4 ,schrader 7for himself1 ,mr4 ,guthrie1 and ,mr4 ,mullin7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend title ,,xix of the ,social ,security ,act to codify value-based purchasing arrangements under the ,medicaid program and reforms related to price reporting under such arrangements1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,medicaid ,v,b,ps for ,patients ,act or the ,,mvp ,act4 #b4 ,findings ,the ,congress finds the following3 7#a7 ,value-based payment 7,,vbp7 arrangements are a critical component of a modernized reimbursement system4 ,by codifying elements of the recently finalized 8multiple best price0 policies of the ,centers for ,medicare ,medicaid ,services1 ,congress is enshrining a sustainable and flexible payment approach for innovative treatments and cures4 7#b7 ,many of these treatments1 including gene therapies1 are different from traditional pharmaceutical and biologic products in that they can offer long-lasting--sometimes lifelong--benefits for patients and long-term value for the health care system alike4 7#c7 ,there are hundreds of innovative1 curative1 and life-changing treatments currently in development in the ,united ,states4 ,however1 the current reimbursement structure was not designed with these therapies in mind1 and allowing for innovative payment arrangements will spur greater development and access to future cures and treatments4 7#d7 ,medicaid is currently losing out on innovative ways to ensure patients have access to these treatments1 while private payors continue to see the value provided through flexible payment arrangements4 7#e7 ,,vbp arrangements include the ability to pay based on evidence-based outcomes and1 over time1 spreading the risk across all entities involved in the contract and ensuring that these often costly treatments are accessible4 7#f7 ,evidence-based outcomes can demonstrate decreased cost to the health system and to patients1 including reduced hospitalizations and lower utilization of other health care expenditures1 including lab work1 other medications1 and office visits4 7#g7 ,by allowing ,v,b,ps in ,medicaid1 the health care system will continue to move towards quality over quantity1 holding manufacturers and providers accountable for the best treatment for every patient4 #c4 ,codifying value-based purchasing arrangements under ,medicaid and reforms related to price reporting under such arrangements 7a7 ,codifying the ,,vbp rule ,the revision to section #ddg4eje7;a7 of title #db1 ,code of ,federal ,regulations related to the inclusion of varying best price points available under a value-based purchasing arrangement 7as defined in section #aibg7k77#ab7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7k77#ab71 as added by subsection 7d7 of this section7 for a single dosage form and strength of a covered outpatient drug if a manufacturer offers such pricing structure to all ,states1 as published by the ,secretary of ,health and ,human ,services on ,december #ca1 #bjbj 7#he ,federal ,register #hgjjj71 shall have the force and effect of law4 7b7 ,quarterly reporting obligation 7#a7 ,in general ,section #aibg7;b77#c77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;b77#c77;,a77 is amended-- 7,a7 in clause 7iv71 by striking at the end and2 7,b7 in clause 7v71 by striking at the end the period and inserting 2 and2 7,c7 by inserting after clause 7v7 the following new clause3 7vi7 for calendar quarters beginning on or after ,july #a1 #bjbb1 in conjunction with reporting required under clause 7i71 in the case of a covered outpatient drug that is sold under a value-based purchasing arrangement 7as defined in subsection 7k77#ab77 made available by the manufacturer to a ,state plan-- 7,i7 the pricing structure for such drug based on pre-defined outcomes or measures specified in such value-based purchasing arrangement2 and 7,,ii7 the best price for such covered outpatient drug outside of a value-based purchasing arrangement1 which in the event such drug is sold exclusively through such an arrangement1 means the lowest price available net of any discounts or offsets that are unrelated to a refund1 rebate1 reimbursement1 free item1 withholding1 or repayment made under a value-based purchasing arrangement for such drug4 2 and 7,d7 by adding at the end of the flush left matter at the end the following new sentence3 ,information reported with respect to a rebate period under clause 7i77,i7 relating to average manufacturer price and clause 7i77,,ii7 relating to best price shall be updated for such rebate period if1 subsequent to the date such information was reported1 cumulative discounts1 rebates1 or other arrangements adjust such average price actually realized or best price available to the extent that such cumulative discounts1 rebates1 or other arrangements are not excluded under this section from the determination of average manufacturer price or best price4 7#b7 ,rules of construction ,nothing in the amendments made by paragraph 7#a7 shall be construed as-- 7,a7 requiring-- 7i7 a ,state to enter into a value-based purchasing arrangement with a manufacturer for a covered outpatient drug2 or 7ii7 a manufacturer to enter into a value-based purchasing arrangement with a ,state for a covered outpatient drug2 7,b7 prohibiting a manufacturer from treating a value-based purchasing arrangement as a bundled sale2 or 7,c7 precluding the execution of a supplemental rebate agreement1 as provided in section #aibg7;a77#a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;a77#a771 for a covered outpatient drug sold under a value-based purchasing arrangement4 7c7 ,definition of average manufacturer price ,section #aibg7k77#a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7k77#a77 is amended-- 7#a7 in subparagraph 7,b77i7-- 7,a7 in subclause 7,,iv71 by striking at the end and2 7,b7 in subclause 7,v71 by striking the period at the end and inserting 2 and2 and 7,c7 by adding at the end the following new subclause3 7,,vi7 in accordance with subsection 7b77#c77;,a77vi71 with respect to such covered outpatient drug that is sold under a value-based purchasing arrangement 7as defined in paragraph 7#ab77 during the rebate period-- 7aa7 a refund1 rebate1 reimbursement1 or free goods from the manufacturer or third party on behalf of the manufacturer2 or 7bb7 the withholding or reduction of a payment to the manufacturer or third party on behalf of the manufacturer2 that is triggered by a patient who fails to achieve outcomes or measures defined under the terms of such value-based purchasing arrangement during the period for which such agreement is effective4 2 and 7#b7 by adding at the end the following new subparagraph3 7,d7 ,special rule for certain value-based purchasing arrangements ,for purposes of subparagraph 7,a71 in determining the average price paid to the manufacturer for a covered outpatient drug that is sold under a value-based purchasing arrangement 7as defined in paragraph 7#ab77 that provides that payment for such drug is made in installments over the course of such agreement1 such price shall be determined as if the aggregate price per the terms of the agreement was paid in full in the first installment during the rebate period4 4 7d7 ,definition of value-,based purchasing arrangement ,section #aibg7k7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7k77 shall be amended by adding at the end the following paragraph3 7#ab7 ,value-,based ,purchasing ,arrangement ,the term value-based purchasing arrangement means an arrangement or agreement intended to align pricing or payments to an observed or expected therapeutic or clinical value in a select population and includes-- 7,a7 evidence-based measures1 which substantially link the cost of a covered outpatient drug to existing evidence of effectiveness and potential value for specific uses of that product2 or 7,b7 outcomes-based measures1 which substantially link payment for the covered outpatient drug to that of the drug's actual performance in patient or a population1 or a reduction in other medical expenses4 4 7e7 ,effective date ,the amendments made by this section shall apply beginning on ,july #a1 #bjbb4 #d4 ,remuneration in ,federal health care programs 7a7 ,in general ,section #aabh;,b7b77#c7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acbj;a-#g;b7b77#c77 is amended-- 7#a7 in subclause 7,j7-- 7,a7 by moving the left margin of such subparagraph #b ems to the left2 and 7,b7 by striking and after the semicolon at the end2 7#b7 in subclause 7,k7-- 7,a7 by moving the left margin of such subparagraph #b ems to the left2 and 7,b7 by striking the period at the end and inserting 2 and2 and 7#c7 by adding at the end the following new subparagraph3 7,l7 any remuneration provided by a manufacturer or third party on behalf of a manufacturer to a plan under a value-based purchasing arrangement 7as defined in section #aibg7k77#ab77 in the case a patient fails to achieve outcomes or measures defined in such arrangement following the administration of a covered outpatient drug 7as defined in section #aibg7k77#b774 4 7b7 ,effective date ,the amendments made by this section shall apply beginning on ,july #a1 #bjbb4 #e4 ,,gao study and report on use of value-based purchasing arrangements 7a7 ,study ,the ,comptroller ,general of the ,united ,states shall conduct a study on the extent to which value-based purchasing arrangements 7as defined in section #aibg7k77#ab7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7k77#ab77 facilitate patient access to covered outpatient drugs1 improve patient outcomes1 lower overall health system costs1 and lower costs for patients in ,federal health care programs4 ,in conducting such study1 the ,comptroller ,general shall-- 7#a7 study the impact of this ,act on-- 7,a7 access to transformative therapies1 including rare disease gene therapies1 generally2 7,b7 mitigating socioeconomic disparities in accessing covered outpatient drugs sold under value-based purchasing arrangements through its requirement that ,state ,medicaid programs have access to the same value-based purchasing arrangement pricing structure that are available in the commercial market for such drugs2 and 7,c7 the ,medicaid drug rebate program under section #aibg of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h71 the #cdj;,b drug pricing program under section #cdj;,b of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bef;b71 and part ,b of title ,,xviii of the ,social ,security ,act 7#db ,u4,s4,c4 #acie;j et seq471 including compliance with such programs2 and 7#b7 using data submitted pursuant to clause 7vi7 of section #aibg7;b77#c77;,a7 of the ,social ,security ,act 7#db ,u4,s4,c4 #acifr-#h7;b77#c77;,a771 as added by section #c of this ,act1 analyze all the types of value-based purchasing arrangement pricing structures1 which structures are working well 7as measured by price and ease of implementing71 and which need improvement4 7b7 ,report ,not later than ,june #cj1 #bjbg1 the ,comptroller ,general of the ,united ,states shall submit to ,congress a report containing the results of the study conducted under subsection 7a74